<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02968160</url>
  </required_header>
  <id_info>
    <org_study_id>YMC017</org_study_id>
    <nct_id>NCT02968160</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Linical Korea</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Randomized, open-label, 2 groups, parallel design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study objective is to compare the safety and efficacy between fixed dose combination
      (Duowell® tab) and free pill combination therapy of Telmisartan and Rosuvastatin in
      hypertensive and hypercholesterolemic patients with metabolic syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects that the mean Sitting Diastolic Blood Pressure(siSBP) and Low Density Lipoprotein-Cholesterol(LDL-C) level reach the treatment goals after 8 weeks from investigational product administration.</measure>
    <time_frame>week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Low Density Lipoprotein-Cholesterol(LDL-C) from baseline to 4 and 8 weeks</measure>
    <time_frame>From baseline to 4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Sitting Systolic Blood Pressure(siSBP) and Sitting Diastolic Blood Pressure(siDBP) from baseline to 4 and 8 weeks</measure>
    <time_frame>From baseline to 4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects that the mean sitting blood pressure(siBP) level reaches the treatment goals to 4 and 8 weeks</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects that the Low Density Lipoprotein-Cholesterol(LDL-C) level reaches treatment goals in accordance with guideline of National Cholesterol Education Program-Adult Treatment Panel(NCEP ATP) III to 4 and 8 weeks</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of below indicators from baseline to 4 and 8 weeks</measure>
    <time_frame>baseline to 4 and 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Telmisartan+Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duowell ® tablet (Telmisartan 40mg + Rosuvastatin 20mg) 1 tablet, once daily, Oral administration/ 8 weeks
* But, the increased Duowell ® tablet (Telmisartan 80mg + Rosuvastatin 20mg) will get administrated orally one tablet once daily to the subjects who have mean systolic blood pressure more than 140mmHg based on arm, which was determined before, at 4week visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan/Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan 40mg + Rosuvastatin 20mg 2 tablets, once daily, Oral administration/ 8 weeks
* But, the increased Telmisartan 80mg + Rosuvastatin 20mg will get administrated orally 2 tablets once daily to the subjects who have mean systolic blood pressure more than 140mmHg based on arm, which was determined before, at 4week visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 40mg + Rosuvastatin 20mg</intervention_name>
    <arm_group_label>Telmisartan+Rosuvastatin</arm_group_label>
    <other_name>Duowell ® tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 80mg + Rosuvastatin 20mg</intervention_name>
    <arm_group_label>Telmisartan+Rosuvastatin</arm_group_label>
    <other_name>Duowell ® tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 40mg, 80 mg</intervention_name>
    <arm_group_label>Telmisartan/Rosuvastatin</arm_group_label>
    <other_name>Micardis tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20mg</intervention_name>
    <arm_group_label>Telmisartan/Rosuvastatin</arm_group_label>
    <other_name>Monorova tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 19 and 79 years old at screening visit

          -  Subjects who have being used anti-hypertension drugs and Lipid lowering agents over
             4weeks before randomization.

          -  Subjects who have been diagnosed with metabolic syndrome according to following
             criteria Definition of patients with metabolic syndrome: Patients satisfy two of the
             following criteria at least

               -  Abdominal obesity: Waist measurement &gt; 90 cm(male), &gt; 80 cm(female)

               -  Triglyceride(TG) ≥ 150 mg/dL(

               -  High-Density Lipoprotein Cholesterol(HDL-C) &lt; 40 mg/dL(male), &lt; 50 mg/dL (female)

               -  Fasting Plasma Glucose(FPG) ≥ 100 mg/dL or Subject who has being used oral
                  hypoglycemic agents

          -  Childbearing potential women have certainly negative of the pregnancy test at
             screening visit (visit 1), and agree to implement the effective contraception during
             the study period(including the medically non-pregnant state)

          -  Subjects who have signed after fully understanding the purpose, content,
             characteristics and risk of the investigational product and get explained enough.

        Exclusion Criteria:

          -  Subjects who taking anti-hypertension drugs more than three agent

          -  Subjects who have mean Sitting Systolic Blood Pressure(siSBP) &gt; 160 mmHg (excluded if
             appliable, one of the arms)

          -  Subjects who have blood pressure ≥ 140/90 mmHg with taking 2 or more anti-hypertension
             drugs (except if any of the arms)

          -  Subjects that Low Density Lipoprotein-Cholesterol(LDL-C) isn't properly controlled
             according to National Cholesterol Education Program Adults Treatment Panel (NCEP ATP)
             III criteria

          -  Subjects who have triglyceride (TG) ≥ 400mg/dL

          -  Subjects who have a difference more than 20mmHg at the mean Sitting Diastolic Blood
             Pressure(siSBP) measured three times in both arms.

          -  Other exclusions applied
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrew Lee</last_name>
    <phone>+82-2-828-0433</phone>
    <email>andrew90@yuhan.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyeongmin Yun</last_name>
    <phone>+82-2-2038-8700</phone>
    <email>Hyeongmin.Yun@linical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dongguk University Medical Center</name>
      <address>
        <city>Ilsan</city>
        <zip>10326</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2016</study_first_submitted>
  <study_first_submitted_qc>November 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2016</study_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

